+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 25 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating molnupiravir, a study medicine designed to stop the COVID-19 virus from multiplying, to see if it can prevent severe illness from COVID-19 more effectively than a placebo in people who are at high risk. The focus is on non-hospitalized adults with COVID-19 who have certain health conditions or factors that increase their chance of severe illness, which can require hospitalization or lead to death. Participants will be randomly assigned to receive either 800 mg of molnupiravir orally every 12 hours for 5 days a total of 10 doses or a matching placebo on the same schedule. Some participants may also receive remdesivir as standard care if clinically appropriate. This is a phase 3, double-blind, placebo-controlled study comparing molnupiravir versus placebo. During the study, participants will be monitored for up to 29 days for outcomes such as hospitalization, death, and COVID-19-related medically attended visits. Researchers will assess adverse events and discontinuation due to side effects over approximately 5 months. Other measures include tracking symptom relief, changes in virus levels, and need for medical interventions. The total participation duration covers treatment and follow-up monitoring to evaluate safety and effectiveness.

Age: 18Years +All GendersPhase 3
227 locations
P

Actively Recruiting

Researchers are evaluating Dostarlimab compared to a placebo in adults with locally advanced unresected Head and Neck Squamous Cell Carcinoma HNSCC. This phase 3 trial aims to assess the safety and effectiveness of Dostarlimab as a sequential therapy following chemoradiation treatment in participants with this type of cancer. Participants are randomly assigned to receive either Dostarlimab or a placebo, both given as intravenous infusions. The study is double-blind, meaning neither the participants nor the researchers know which treatment is being given. The treatments follow completion of chemoradiation with cisplatin and radiotherapy intended to cure the cancer. During the study, participants will be monitored for up to approximately 5 years. Researchers will evaluate event-free survival and overall survival, with safety assessments including treatment-emergent adverse events and laboratory tests. Blood samples will be taken to measure drug levels and immune responses. This long-term follow-up will help understand the effects and safety of Dostarlimab after chemoradiation therapy.

Age: 18Years +All GendersPhase 3
277 locations
O

Actively Recruiting

Advanced Parkinsons disease is a neurological condition characterized by symptoms such as tremors, stiffness, and slowed movements. This observational study evaluates changes in sleep disturbances in adults with advanced Parkinsons disease who are receiving subcutaneous FoslevodopaFoscarbidopa. The study is conducted under routine clinical practice with approximately 103 adult participants across about 20 sites in Spain. Participants will be treated with FoslevodopaFoscarbidopa delivered via subcutaneous infusion as prescribed by their doctors according to the local label. The study involves no additional treatment burden and follows participants for up to 12 weeks while they continue their prescribed therapy. During the study, participants will attend regular hospital or clinic visits aligned with their standard clinical care. Researchers will assess changes in Parkinsons disease-related sleep disturbances using the Parkinsons Disease Sleep Scale - 2 PDSS-2 over approximately 12 weeks. The study monitors participants without altering their routine treatment and collects data on sleep disturbances and other relevant health outcomes.

Age: 18Years +All Genders
16 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and tolerability of two drug combinations Cabotegravir Ultra Long-Acting CAB ULA plus Rilpivirine Ultra Long-Acting RPV ULA, and Cabotegravir Long-Acting CAB LA plus Rilpivirine Long-Acting RPV LA in adults and adolescents living with HIV who have their virus suppressed through antiretroviral therapy ART. This phase III trial aims to compare these treatments to understand their impact on maintaining viral suppression. Participants receive either the CAB ULA plus RPV ULA combination or the CAB LA plus RPV LA combination. These medications are administered as long-acting injectable drugs. The study uses a randomized, parallel-group design where participants are assigned to one of these two treatment groups to compare outcomes over time. During the trial, participants will be monitored closely with regular assessments including measuring plasma HIV-RNA levels, tracking any virologic failure, and evaluating drug-related adverse events. Laboratory tests will monitor drug concentrations and immune cell counts CD4 cells. The main outcome is the percentage of participants with HIV-RNA levels above 50 copiesmL at month 11. The study follows participants for up to 23 months to assess longer-term effects and safety.

Age: 12Years +All GendersPhase 3
108 locations
C

Actively Recruiting

Researchers are collecting detailed information about patients with venous thromboembolism VTE to improve understanding of this condition, especially in groups often excluded from clinical trials such as pregnant women, elderly patients, and those with severe health issues. This observational registry aims to provide data that can help reduce death rates, recurrences of blood clots, bleeding problems, and arterial events related to VTE. This study gathers clinical details about each patient, including other health conditions, and tracks the type, dose, duration, and results of antithrombotic treatments over the first three months. The registry is accessible online to assist doctors in managing complex cases by comparing patient profiles and identifying those at higher risk of complications. Participants clinical status and treatment outcomes are recorded, focusing on recurrence of VTE, bleeding events, and mortality over a three-year period. The information supports the creation of predictive scores to help healthcare providers identify patients at higher risk. The study started in 2001 and plans to continue until 2027, with ongoing data collection and follow-up.

All AgesAll Genders
305 locations
P

Actively Recruiting

Researchers are evaluating whether continuing cetuximab treatment beyond first-line progression can improve outcomes in adults with metastatic colorectal cancer who have tumors that are RAS and BRAF wild-type. This Phase 3 clinical trial aims to compare chemotherapy combined with cetuximab versus chemotherapy combined with bevacizumab, focusing on tumor response, progression-free survival, overall survival, and safety. The study builds on prior trials suggesting potential benefits of cetuximab continuation in this patient group. Participants will be randomly assigned to receive either FOLFOX or FOLFIRI chemotherapy combined with cetuximab experimental group or bevacizumab control group. Treatments are given every two weeks, with cetuximab administered as a 120-minute intravenous infusion at 500 mgm and bevacizumab at 5 mgkg. Therapy continues until disease progression, unacceptable side effects, or patient withdrawal. Tumor response will be assessed by independent review using RECIST criteria. During the study, patients undergo regular CT or MRI scans, laboratory tests, and clinical evaluations. Biological samples such as tumor tissue, blood, and stool are collected for research on resistance mechanisms and the gut microbiome. The primary measure is the overall response rate assessed up to 48 months, with secondary outcomes including overall survival, progression-free survival, and safety monitored throughout treatment and up to 30 days after the last dose. Participation lasts through treatment and follow-up periods up to several years.

Age: 18Years +All GendersPhase 3
41 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are developing and validating a predictive model to understand the risk of acquiring sexually transmitted infections STIs among individuals using HIV pre-exposure prophylaxis PrEP within Spains national program. This observational study includes PrEP users followed according to national protocols at 23 hospitals. The study focuses on STIs such as syphilis, gonorrhea, chlamydia, herpes, hepatitis, HIV, and MPOX, with the primary outcome being whether participants develop an STI. Participants are individuals who have started daily oral PrEP, have taken at least one pill, and meet the approved criteria by Spanish guidelines. They will be monitored quarterly with tests including blood samples and swabs from various sites to diagnose STIs. The study uses data from these visits to build and validate predictive models and analyze factors linked to STI acquisition. Participants will be followed over an average of five years with regular clinical visits to monitor for STIs and collect behavioral and adherence data. Researchers will measure the occurrence and number of STIs, changes in behavior, PrEP adherence, and discontinuation rates. The study aims to improve understanding of STI dynamics among PrEP users while ensuring ongoing monitoring and data collection throughout the participation period.

Age: 16Years +All Genders
26 locations
E

Actively Recruiting

Researchers are collecting real-world data from cancer patients who receive radiotherapy to better understand the role of radiation oncology within a multidisciplinary treatment approach. This open-ended, prospective, non-interventional study aims to support radiotherapy research by observing patients over time without providing therapeutic interventions. The study includes patients with various cancer types who are planned to receive radiotherapy. Participants include patients treated with radical radiotherapy for oligometastatic disease as well as those receiving high-dose re-irradiation. The study is organized into multiple cohorts, such as OligoCare and ReCare, based on the type of radiotherapy treatment. Since it is an observational study, no experimental treatments or placebos are given. During the study, researchers will collect data on patient outcomes including disease-free survival, loco-regional control, distant metastasis-free survival, overall survival, and any adverse events related to radiotherapy over a period of five years. The main measure is the number of patients treated with radiotherapy enrolled in the program. Participants will have their health and treatment effects monitored regularly throughout this timeframe to provide valuable information about radiotherapy outcomes in real-world clinical settings.

Age: 12Years +All Genders
77 locations
S

Actively Recruiting

Researchers are evaluating a smartphone app called Digital Solution for Pain in Adolescents Digital SPA designed to help children and adolescents aged 12 to 17 years who have chronic pain. This study aims to co-develop the app with patients, test its usability, and implement it as a tool to provide pain management resources and prevent future disability. The study is divided into multiple phases including focus groups, content creation, and an effectiveness and implementation study. The intervention uses validated psychological methods, especially Cognitive Behavioral Therapy and Acceptance and Commitment Therapy, to teach pain coping skills such as relaxation, goal setting, sleep management, behavioral activation, self-management of negative thoughts and emotions, and communication skills. Participants will be randomly assigned to either use the Digital SPA app or receive usual care at their hospital. The app was co-created with patients based on their input and current evidence-based guidelines. Participants will take part in individual and group interviews, complete online questionnaires, and use the smartphone app during the study. Researchers will measure changes in pain interference, emergency room visits due to pain, pain readiness to change, medication use, emotional distress, functional disability, sleep quality, pain self-efficacy, psychological flexibility, treatment satisfaction, and adherence over several time points from before treatment, mid-treatment, post-treatment, and at a 3-month follow-up. The total study duration includes an 8-week treatment period and follow-up assessments at 3 months after treatment completion.

Age: 12Years - 17YearsAll GendersPhase Not Applicable
6 locations
S

Actively Recruiting

Researchers are evaluating the effectiveness and safety of subcutaneous immunotherapy SCIT in people aged 12 to 65 who have allergic rhinitis or rhinoconjunctivitis, with or without mild to moderate asthma. The study focuses on patients sensitized to specific house dust mites, Dermatophagoides pteronyssinus andor Dermatophagoides farinae. This is a phase 3, double-blind, placebo-controlled, randomized trial conducted at multiple centers. Participants will be randomly assigned to one of three groups two receive different doses of SCIT 10,000 TUmL or 30,000 TUmL of allergenic extract, and one receives a placebo injection without active ingredients. Treatment lasts for one year, with doses administered subcutaneously. The study compares the two active treatment groups to the placebo group to determine which dose may be more effective and safe. During the trial, participants will be closely monitored for symptoms and medication use, assessed by the Combined Symptoms and Medication Score CSMS over 12 months. Researchers will also track medication-free days, symptom-free days, quality of life related to asthma and rhinitis, adverse events, and immunological responses. Participants will log symptoms and medication use via smartphone. Safety and treatment effects will be evaluated throughout the study period.

Age: 12Years - 65YearsAll GendersPhase 3
32 locations

1-10 of 25

1